ArticleAntimicrobial agents and chemotherapy2021
Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Pooled it
- Pooled it
- Pooled it
- Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-ResistantMicrobiology spectrum · 2022Pooled it
- Risk factors for polymicrobial klebsiella pneumoniae bloodstream infection: a retrospective cohort study using the antimicrobial resistance monitoring database.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Epidemiology, antimicrobial resistance, and mortality of bloodstream infections in hemodialysis patients: an 11-year retrospective cohort study from southern Saudi Arabia.BMC nephrology · 2026Article
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
- Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026Article
- An Algorithm for Rapid and Low-Cost Detection of Carbapenemases Directly from Positive Blood Cultures Using an Immunochromatographic Test.Antibiotics (Basel, Switzerland) · 2025Article
- Comparison between cefepime and carbapenem therapy for deep-seated AmpC-producingAntimicrobial agents and chemotherapy · 2025Article
- Ceftazidime/Avibactam Monotherapy Versus Other Antibiotics: Where Do We Stand?Pathogens (Basel, Switzerland) · 2025Review
- Risk Factor Analysis of CRE Infections at Different Anatomical Sites in ICU Patients.Antibiotics (Basel, Switzerland) · 2025Article
- REL/DPA/AVI method: a novel approach for rapid detection of carbapenemase-producing Enterobacterales directly from positive blood cultures based on optical density.Journal of clinical microbiology · 2025Article
- Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025Article
- Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.Infectious diseases and therapy · 2025Article
- Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales.Antibiotics (Basel, Switzerland) · 2025Article
- Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.BMC infectious diseases · 2025Article
- A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Efficacy of ceftazidime/avibactam versus other antimicrobial agents for treating multidrug- resistantFrontiers in cellular and infection microbiology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSIs) attributable to carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.